Softbank China and Sinopharm-CICC Capital returned for a series B-plus round after backing the online pharmacy's 2019 series B.
China-based online pharmacy Dingdang Kuaiyao secured RMB1bn ($150m) yesterday in a series B-plus round featuring vehicles for telecommunications and internet group SoftBank and pharmaceutical firm Sinopharm, South China Morning Post reported.
Softbank China and Sinopharm-CICC Capital, a joint venture between Sinopharm and investment manager China International Capital Corporation, joined other existing investors including financial services firm China Merchants Bank’s CMB International unit in the round.
Dingdang operates an online pharmacy that offers sub-30 minute delivery of medication through certain distances…
